Sustained Stability in High-Risk Grade 3 Breast Cancer with Inflammatory feature

A Malaysian, 50-year-old female patient was diagnosed with right breast invasive ductal carcinoma with inflammatory characteristics, high histological grade (grade 3), and lymph node involvement diagnosed in 2022. One out of three lymph nodes demonstrated metastatic involvement with focal extranodal extension. Pathological staging was pT2N1Mx. The tumor was ER and PR positive and HER2 negative, placing the patient in a higher recurrence risk within 2 years for this category despite hormone receptor positivity.

Following surgery and chemotherapy, she commenced ECCT in 2022 as part of her ongoing health management and recovery plan due to the high recurrence rate.

Since initiating ECCT, the patient has remained clinically stable and in good general health. She has been able to maintain mobility, daily activities, and overall quality of life throughout the course of treatment. Her progress has been closely monitored with regular follow-up consultations and imaging studies.

Over the subsequent three years, serial investigations including PET scans, mammograms, breast ultrasounds, chest X-rays, and abdominal ultrasounds have consistently shown no evidence of cancer recurrence or distant metastatic disease. Findings observed in earlier imaging, such as post-treatment inflammatory changes, resolved on follow-up without progression, supporting sustained disease control.

As of the most recent assessments in 2025, imaging confirms only post-surgical changes in the right breast with benign findings bilaterally (BIRADS 2). There is no radiological or clinical indication of active malignancy.

This case highlights the role of ECCT as a supportive and complementary approach during the post-treatment phase of cancer care to prolonged survival and prevent recurrent. Through structured treatment protocols, regular monitoring, and individualized adjustments, ECCT has helped the patient maintain long-term stability, confidence, and peace of mind during survivorship.

More than three years after diagnosis, the patient continues to remain healthy and recurrence-free while on ECCT, demonstrating its value as part of a comprehensive, long-term health support strategy for High-Risk Grade 3 Breast Cancer with Inflammatory.